MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 4 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $627,000 | +29.8% | 246,745 | +3.7% | 0.00% | – |
| Q1 2020 | $483,000 | +71.3% | 237,907 | +82.5% | 0.00% | – |
| Q4 2019 | $282,000 | +40.3% | 130,390 | 0.0% | 0.00% | – |
| Q3 2019 | $201,000 | -64.7% | 130,390 | -4.9% | 0.00% | – |
| Q2 2019 | $569,000 | -6.0% | 137,060 | -5.3% | 0.00% | – |
| Q1 2019 | $605,000 | +100.3% | 144,669 | +37.4% | 0.00% | – |
| Q4 2018 | $302,000 | -72.7% | 105,291 | -4.7% | 0.00% | – |
| Q3 2018 | $1,105,000 | +46.6% | 110,480 | +3.7% | 0.00% | – |
| Q2 2018 | $754,000 | +438.6% | 106,560 | +190.4% | 0.00% | – |
| Q1 2018 | $140,000 | -48.3% | 36,697 | +10.5% | 0.00% | – |
| Q4 2017 | $271,000 | +111.7% | 33,209 | +52.0% | 0.00% | – |
| Q3 2017 | $128,000 | +255.6% | 21,842 | +8.0% | 0.00% | – |
| Q1 2017 | $36,000 | +71.4% | 20,229 | +22.8% | 0.00% | – |
| Q2 2016 | $21,000 | -76.4% | 16,474 | -0.4% | 0.00% | – |
| Q1 2016 | $89,000 | – | 16,535 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 5,042,735 | $14,473,000 | 4.95% |
| VHCP Management III, LLC | 1,258,964 | $3,613,000 | 2.63% |
| Granite Point Capital Management, L.P. | 2,659,367 | $7,632,000 | 1.54% |
| Granite Point Capital Management, L.P. | 1,600,000 | $4,592,000 | 0.93% |
| VHCP Management II, LLC | 743,876 | $2,135,000 | 0.92% |
| Monashee Investment Management LLC | 250,000 | $718,000 | 0.49% |
| 683 Capital Management, LLC | 1,350,000 | $3,875,000 | 0.24% |
| CAXTON CORP | 61,443 | $176,000 | 0.21% |
| Tekla Capital Management LLC | 755,776 | $2,169,000 | 0.09% |
| Fosun International Ltd | 491,997 | $1,378,000 | 0.08% |